Key result
Treatment with transcatheter arterial chemoembolization and subsequent anlotinib for recurrent metastasis resulted in no tumor progression in a 69-year-old female with HEHE.
Why the study?
Hepatic epithelioid hemangioendothelioma is rare, making its diagnosis and treatment challenging.
Case Report (n=1)
Anlotinib may stabilize recurrent intrahepatic metastasis of hepatic epithelioid hemangioendothelioma following initial treatment with transcatheter arterial chemoembolization.
May support anlotinib in recurrent hepatic epithelioid hemangioendothelioma; hypothesis-generating and requires prospective validation.
Epithelioid hemangioendothelioma is a low-grade malignant tumor of vascular origin. The rarity of hepatic epithelioid hemangioendothelioma (HEHE) makes the diagnosis and treatment of this entity challenging. We report a case of a 69-year-old female patient who suffered from HEHE and complained of abdominal distension pain with dizziness and appetite loss for more than half a month. Enhanced computed tomography of the upper abdomen indicated multiple space-occupying lesions in the liver. The pathological results of color ultrasound puncture suggested HEHE. We performed transcatheter arterial chemoembolization and relevant examinations according to the patient's condition and their choice. We followed the patient for 5 years and found that she developed recurrent intrahepatic metastasis of the tumor. Computed tomography was performed again after 3 months of treatment with anlotinib and the tumor did not show any progression. HEHE is a relatively rare hepatic malignant tumor derived from vascular endothelial cells, with a low incidence, atypical clinical manifestations, and a difficult diagnosis that can only be confirmed with pathological results. Currently, appropriate treatment methods should be selected according to the specific conditions of the patient.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2024) conducted a case report in Hepatic epithelioid hemangioendothelioma (n=1). Transcatheter arterial chemoembolization and anlotinib was evaluated. Treatment with transcatheter arterial chemoembolization and subsequent anlotinib for recurrent metastasis resulted in no tumor progression in a 69-year-old female with HEHE.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: